Navigation Links
French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart

Tucson, AZ (PRWEB) August 15, 2013

Due to the global shortage of donor hearts, patients on the waiting list for a heart transplant can wait several months to several years for a match to be found. But for 36-year-old Frédéric Thiollet, who surpassed two years of support with the SynCardia temporary Total Artificial Heart on Aug. 5, he’s enjoying each and every day.

“I feel well and I am confident, having been implanted now for over two years,” said Frédéric Thiollet. “I have recuperated all my physical functions, even my sexual activity, which I had believed was gone forever. In my own words, I have enjoyed an effective resurrection, a new birth. Physically I have no limit. I am as strong and powerful as before, even more so than before.”

Prior to receiving the Total Artificial Heart in 2011, Frédéric Thiollet said, “I was clearly waiting for my last breath.” Despite being hungry and tired, he found himself unable to eat or sleep. The simplest efforts made him short of breath. He could no longer wash himself or get dressed by himself and was unable to talk. During a two-month period, he lost 32 kg (70 pounds), shrinking from 82 kg (180 pounds) to 50 kg (110 pounds).

“This young man was in severe global heart failure,” said Prof. Daniel Duveau, medical director of the Thorax Institute at University Hospital of Nantes in France. “We chose the SynCardia Total Artificial Heart for several reasons. During our 25-year experience, the Total Artificial Heart has produced better results than any other biventricular support device. For example, at our hospital, 75% of Total Artificial Heart patients received a transplant compared to only 40% of p-VAD patients. In addition, other biventricular support devices, even those totally implanted, provide a poor quality of life. The SynCardia Total Artificial Heart powered by the Freedom® portable driver provides patients with the mobility they need to resume life at home, as proven by Mr. Thiollet.”

Frédéric Thiollet was implanted with the SynCardia Total Artificial Heart on Aug. 5, 2011. Within two months of the surgery, he had gained back 35 kg (77 pounds) and was exercising daily for 4 to 5 hours, doing light weights and riding a stationary bicycle.

He has been waiting for a matching donor heart at home since Dec. 15, 2011, using the Freedom portable driver, the world’s first wearable power supply for the SynCardia Total Artificial Heart. He has been supported by the Freedom driver for more than 700 days.

“The benefit of the Freedom driver is invaluable,” said Frédéric Thiollet. “I have been able to return to my daily life with my family instead of having to wait for a donor heart for many months or years in the hospital. Due to the high level of antibodies in my system, finding a heart for me will be almost impossible. However, I will continue to go on in my own way thanks to the Total Artificial Heart. It allows me to love every day of life, and will continue to do so for a long time to come.”


About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
2. No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
3. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
4. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
5. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
6. Accuray Surpasses 600 Installations Globally
7. OrganJet customer receives kidney transplant years faster due to smart multiple listing
8. Food Safety Microbiology Testing Increases 40% in 5 Years to $2.9 Billion Worldwide
9. Vetter Offers a Sterile Water-for-injection Solution with 5 Years Stability Data
10. Humphreys & Associates Announces 40+ Years of Participation in the NDIA's Program Management Systems Committee (PMSC) and Will Attend the 2013 NDIA Event from June 17-20
11. Davron Technologies Beats the Post-recession Odds with Four Years of Net Growth
Post Your Comments:
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
(Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
Breaking Biology News(10 mins):